文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.

作者信息

Roh Jong-Lyel, Kim Eun Hye, Jang Hyejin, Shin Daiha

机构信息

Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

出版信息

Redox Biol. 2017 Apr;11:254-262. doi: 10.1016/j.redox.2016.12.010. Epub 2016 Dec 18.


DOI:10.1016/j.redox.2016.12.010
PMID:28012440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5198738/
Abstract

UNLABELLED: Artesunate, an anti-malarial drug, has been repurposed as an anticancer drug due to its induction of cell death via reactive oxygen species (ROS) production. However, the molecular mechanisms regulating cancer cell death and the resistance of cells to artesunate remain unclear. We investigated the molecular mechanisms behind the antitumor effects of artesunate and an approach to overcome artesunate resistance in head and neck cancer (HNC). The effects of artesunate and trigonelline were tested in different HNC cell lines, including three cisplatin-resistant HNC cell lines. The effects of these drugs as well as the inhibition of Keap1, Nrf2, and HO-1 were assessed by cell viability, cell death, glutathione (GSH) and ROS production, protein expression, and mouse tumor xenograft models. Artesunate selectively killed HNC cells but not normal cells. The artesunate sensitivity was relatively low in cisplatin-resistant HNC cells. Artesunate induced ferroptosis in HNC cells by decreasing cellular GSH levels and increasing lipid ROS levels. This effect was blocked by co-incubation with ferrostatin-1 and a trolox pretreatment. Artesunate activated the Nrf2-antioxidant response element (ARE) pathway in HNC cells, which contributed to ferroptosis resistance. The silencing of Keap1, a negative regulator of Nrf2, decreased artesunate sensitivity in HNC cells. Nrf2 genetic silencing or trigonelline reversed the ferroptosis resistance of Keap1-silenced and cisplatin-resistant HNC cells to artesunate in vitro and in vivo. Nrf2-ARE pathway activation contributes to the artesunate resistance of HNC cells, and inhibition of this pathway abolishes ferroptosis-resistant HNC. CONDENSED ABSTRACT: Our results show the effectiveness and molecular mechanism of artesunate treatment on head and neck cancer (HNC). Artesunate selectively killed HNC cells but not normal cells by inducing an iron-dependent, ROS-accumulated ferroptosis. However, this effect may be suboptimal in some cisplatin-resistant HNCs because of Nrf2-antioxidant response element (ARE) pathway activation. Inhibition of the Nrf2-ARE pathway increased artesunate sensitivity and reversed the ferroptosis resistance in resistant HNC cells.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/08bb0ed74770/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/d8cd0b64095b/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/4df525a16b18/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/a772029c4916/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/31a7d8d6c3db/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/5149c7ece0dd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/53d2192735ad/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/78edf04099d5/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/08bb0ed74770/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/d8cd0b64095b/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/4df525a16b18/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/a772029c4916/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/31a7d8d6c3db/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/5149c7ece0dd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/53d2192735ad/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/78edf04099d5/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b9/5198738/08bb0ed74770/gr7.jpg

相似文献

[1]
Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.

Redox Biol. 2017-4

[2]
Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.

Free Radic Biol Med. 2018-10-16

[3]
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.

Cancer Lett. 2016-7-28

[4]
RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.

Redox Biol. 2017-6-1

[5]
Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.

Apoptosis. 2016-11

[6]
A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.

Mol Cancer Ther. 2016-11

[7]
Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.

Antioxid Redox Signal. 2016-11-14

[8]
Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.

Oxid Med Cell Longev. 2017-12-31

[9]
CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.

Cancer Lett. 2018-6-18

[10]
Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.

Cancer Lett. 2016-2-1

引用本文的文献

[1]
Natural Agents Modulating Ferroptosis in Cancer: Molecular Pathways and Therapeutic Perspectives.

J Cell Mol Med. 2025-9

[2]
Synergistic Ferroptosis-Immunotherapy Nanoplatforms: Multidimensional Engineering for Tumor Microenvironment Remodeling and Therapeutic Optimization.

Nanomicro Lett. 2025-9-2

[3]
Ferroptosis and Nrf2 Signaling in Head and Neck Cancer: Resistance Mechanisms and Therapeutic Prospects.

Antioxidants (Basel). 2025-8-13

[4]
Carnitine Shuttle and Ferroptosis in Cancer.

Antioxidants (Basel). 2025-8-8

[5]
Ioning out glioblastoma: ferroptosis mechanisms and therapeutic frontiers.

Cell Death Discov. 2025-8-26

[6]
Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications.

Cell Death Discov. 2025-8-25

[7]
Iron metabolism and ferroptosis in human health and disease.

BMC Biol. 2025-8-22

[8]
Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis.

Cancer Drug Resist. 2025-8-7

[9]
Artesunate inhibits hepatocellular carcinoma cell migration and invasion through OGA-mediated -GlcNAcylation of ZEB1.

Open Life Sci. 2025-8-5

[10]
Unveiling the antioxidant and anti-inflammatory potential of syringic acid: mechanistic insights and pathway interactions.

Front Pharmacol. 2025-7-9

本文引用的文献

[1]
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.

Cancer Lett. 2016-7-28

[2]
Iron and cancer: recent insights.

Ann N Y Acad Sci. 2016-3

[3]
Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate.

Mol Carcinog. 2017-1

[4]
Ferroptosis: process and function.

Cell Death Differ. 2016-3

[5]
Regulated necrosis: disease relevance and therapeutic opportunities.

Nat Rev Drug Discov. 2016-5

[6]
Ferroptosis: Death by Lipid Peroxidation.

Trends Cell Biol. 2016-3

[7]
Artesunate Protects Against Sepsis-Induced Lung Injury Via Heme Oxygenase-1 Modulation.

Inflammation. 2016-4

[8]
Tumor Regression Patterns Based on Follow-up Duration in Patients With Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy or Chemoradiotherapy.

Clin Exp Otorhinolaryngol. 2015-12

[9]
The wisdom of crowds and the repurposing of artesunate as an anticancer drug.

Ecancermedicalscience. 2015-10-13

[10]
Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.

Oncotarget. 2015-10-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索